Pacira Pharma (PCRX) Tops Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Pacira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
February 28, 2018 8:00 AM EST-- EXPAREL® net product sales expected to be in the range of $300 to $310 million in 2018 --
-- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported financial results for the fourth quarter and full year of 2017 and its outlook for 2018.
2017 was a year of solid progress and set the stage for an important year ahead, said Dave Stack, chairman and chief executive officer of Pacira. EXPAREL has now been used in... More
